INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

被引：1
|
作者：
Mursleen, S. [1 ]
Shah, D. [2 ]
Schroeder, M. [3 ]
Perdrizet, J. [2 ]
Ndirangu, K. [2 ]
Risebrough, N. [4 ]
Martin, A. [5 ]
机构：
[1] GSK, Mississauga, ON, Canada
[2] ICON Hlth Econ, New York, NY USA
[3] GSK, Brentford, England
[4] ICON, ICON Hlth Econ, Toronto, ON, Canada
[5] GSK, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2438
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS44
引用
收藏
页码：S411 / S411
页数：1
相关论文
共 50 条
  • [1] INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC
    Schroeder, M.
    Shah, D.
    Mursleen, S.
    Martin, A.
    Perdrizet, J.
    Ndirangu, K.
    Risebrough, N.
    VALUE IN HEALTH, 2018, 21 : S411 - S412
  • [2] INFORMING THE PATHWAY OF COPD TREATMENT (THE IMPACT STUDY): SINGLE INHALER TRIPLE THERAPY (FF/UMEC/ VI) VERSUS FF/ VI IN PATIENTS WITH COPD - COST-EFFECTIVENESS IN THE UK
    Martin, A.
    Shah, D.
    Schroeder, M.
    Ndirangu, K.
    Risebrough, N.
    Anley, G.
    Okorogheye, G.
    Fenwick, E.
    Ismaila, A. S.
    THORAX, 2018, 73 : A237 - A237
  • [3] INFORMING THE PATHWAY OF COPD TREATMENT (THE IMPACT STUDY): SINGLE INHALER TRIPLE THERAPY (FF/UMEC/ VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/ VI) IN PATIENTS WITH COPD - COST-EFFECTIVENESS IN THE UK
    Anley, G.
    Shah, D.
    Schroeder, M.
    Ndirangu, K.
    Risebrough, N.
    Okorogheye, G.
    Fenwick, E.
    Martin, A.
    Ismaila, A. S.
    THORAX, 2018, 73 : A236 - A237
  • [4] Informing the Pathway of COPD Treatment (the Impact Study) - Economic Evaluation of Single-Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI or UMEC/VI in Patients with COPD by Treatment Subgroups at Screening - A Canadian Societal Perspective
    Ismaila, A. S.
    Shah, D.
    Schroeder, M.
    Abreu, C.
    Martin, A.
    Risebrough, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI AND UMEC/VI IN PATIENTS WITH COPD: HEALTHCARE RESOURCE UTILIZATION DATA AND ASSOCIATED COSTS - GERMANY
    Paly, V
    Schroeder, M.
    Martin, A.
    Li, J.
    Wacker, M.
    Risebrough, N.
    Lettis, S.
    Ismaila, A.
    VALUE IN HEALTH, 2018, 21 : S407 - S407
  • [6] The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
    Kato, Motokazu
    Tomii, Keisuke
    Hashimoto, Kenichi
    Nezu, Yasuko
    Ishii, Takeo
    Jones, C. Elaine
    Kilbride, Sally
    Gross, Annette S.
    Clifton, Christine S.
    Lipson, David A.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 2849 - 2861
  • [7] Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial
    Zheng, Jinping
    Zhong, Nanshan
    Wang, Changzheng
    Wei, Li Ping
    Zhou, Xiang Dong
    Zhao, Li
    Dong Yuan, Ya
    He, Bei
    Wu, Bin
    Du, Xin
    Song, Jie
    Lipson, David A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 145 - 155
  • [8] COST-EFFECTIVENESS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS TIOTROPIUM MONOTHERAPY IN PATIENTS WITH COPD IN THE UK
    Martin, A.
    Shah, D.
    Shukla, S.
    Kendall, R.
    Risebrough, N. A.
    Compton, C.
    Ismaila, A.
    VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
  • [9] THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
    Vallejo-Aparicio, L. A.
    Paly, V. F.
    Schroeder, M.
    Martin, A.
    Risebrough, N.
    Abreu, C.
    Biswas, C.
    Izquierdo Alonso, J. L.
    Riesco Miranda, J. A.
    Soler Cataluna, J. J.
    Ismaila, A. S.
    VALUE IN HEALTH, 2019, 22 : S878 - S878
  • [10] Late Breaking Abstract - IMPACT study - single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs - UK
    Ismaila, Afisi
    Paly, Victoria
    Schroeder, Melanie
    Martin, Alan
    Li, Jiahe
    Lettis, Sally
    Risebrough, Nancy
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
12345